SEATTLE, June 25 /PRNewswire-USNewswire/ — Two
global health non-profit organizations headquartered in Seattle, Washington, the Infectious
Disease Research Institute (IDRI) and PATH, have entered into a
Research Collaboration Agreement to evaluate novel adjuvants for
their ability to enhance the immune response of pandemic influenza
vaccines in development. The collaboration supports the goal of
PATH’s influenza vaccine project to advance the development of
promising new influenza vaccines focusing on novel technologies
that can be accessible, affordable, and available to people in
low-resource countries in a global outbreak. IDRI, a non-profit
biotechnology organization, has developed numerous emulsion
adjuvants for use with various antigens for the production of
vaccines.
Influenza vaccines, against both seasonal and pandemic influenza
viruses, are especially needed in developing countries where
current influenza vaccines may be unavailable or unaffordable,
especially in the quantities needed during a pandemic outbreak.
“Adjuvants, or immunostimulants, could be used to increase the
worldwide supply of influenza vaccines, and may be crucial to
provide the necessary doses in the event of a pandemic,” says
IDRI’s Founder and Head of Research and Development Dr. Steve Reed.
Under the Research Collaboration Agreement, PATH will sponsor
research at IDRI to evaluate different emulsions that may work as
effective adjuvants in influenza vaccines for pandemic use. IDRI
will provide its proprietary emulsion formulations, and PATH,
through its collaborators, will provide IDRI with vaccine
candidates for evaluation with various formulations. IDRI will then
conduct the studies to identify leading vaccine-adjuvant
candidates.
“We are
‘/>”/>